NOPAIN for Veterans Act
- Bill Number
- S. 3209
- Origin Chamber
- Senate
- Congress
- 119th Congress, Session 1
- Policy Area
- Armed Forces and National Security
- Status
- Introduced
- Latest Action
- 2025-11-19: Read twice and referred to the Committee on Veterans' Affairs.
- Last Updated
- 2026-02-04T12:03:15Z
AI-Generated Summary
Purpose
The legislation, titled the "Non-Opioids Prevent Addiction in the Nation for Veterans Act" (or "NOPAIN for Veterans Act"), aims to improve access to non-opioid pain relief options for veterans by requiring the Department of Veterans Affairs (VA) to include certain FDA-approved non-opioid medications in its national formulary. This supports efforts to reduce reliance on opioids and prevent addiction among veterans experiencing pain, such as after surgery or from acute injuries.
Key Provisions
- Definition of Non-Opioid Pain Medications: Introduces a specific term for "non-opioid pain management drug or biological product," defined as any drug or biological product approved, granted, or cleared by the Food and Drug Administration (FDA) to reduce postoperative pain, provide postsurgical or regional pain relief (analgesia), or treat acute pain, without interacting with the body's opioid receptors (which are the sites where opioids typically bind to relieve pain).
- Inclusion Timeline in VA Formulary: Mandates that the VA Secretary add these non-opioid products to the department's national formulary (a list of approved medications covered by VA health care) no later than the earlier of:
- One year after the product qualifies for temporary additional payment under a specific Medicare provision (Social Security Act section 1833(t)(16)(G)) or for separate payment under federal regulations (42 CFR section 416.174 or successors).
- 18 months after FDA approval.
- Funding Restriction: Prohibits using funds from the Cost of War Toxic Exposures Fund (a dedicated VA fund for toxic exposure-related care) to implement these changes.
- Implementation Deadline: Requires the VA Secretary to put these amendments into effect within 90 days of the bill's enactment.
Significant Changes to Existing Law
The bill amends section 8125 of title 38, United States Code (which governs the VA's national formulary and drug criteria):
- Adds a new subsection (d) with the inclusion requirements and timeline.
- Redesignates the existing subsection (d) (definitions) as subsection (e) and expands it with the new definition of non-opioid pain management products.
These changes accelerate the addition of qualifying non-opioid medications to the VA formulary, which previously relied on broader VA discretion without a fixed timeline tied to FDA approval or payment eligibility.
Potential Impacts
- On Government Agencies: The VA will need to update its formulary processes and procurement more quickly, potentially increasing administrative workload and costs (though not from the restricted toxic exposures fund). This could streamline VA pharmacy operations by prioritizing non-opioid options.
- On Citizens: Veterans receiving VA health care will gain faster access to non-opioid pain treatments, which may lower the risk of opioid dependency, addiction, and related health issues like overdose. It promotes safer pain management without broadly affecting non-veteran citizens.
- On International Relations: No direct impacts, as the bill focuses on domestic VA operations and U.S.-based FDA approvals.
Main Stakeholders Affected
- Veterans: Primary beneficiaries, especially those with acute, postoperative, or chronic pain, who may receive earlier access to alternative pain relief.
- Department of Veterans Affairs (VA): Responsible for compliance, including timely formulary updates and implementation.
- Pharmaceutical and Biotech Companies: Developers of non-opioid pain products may see faster VA adoption, incentivizing innovation in this area.
- Healthcare Providers in VA System: VA doctors and pharmacists will have expanded non-opioid options for prescribing, potentially shifting treatment protocols.
Notable Legal, Constitutional, or Political Implications
- Legal Implications: Strengthens VA obligations under federal drug policy by imposing enforceable timelines, which could lead to lawsuits if not met. The funding restriction ensures separation from other VA programs, avoiding resource diversion.
- Constitutional Implications: None significant; the bill operates within Congress's authority to regulate federal agencies like the VA and does not infringe on individual rights.
- Political Implications: Addresses the national opioid crisis with a veteran-specific focus, building bipartisan support (evident from co-sponsors across parties). It may influence broader health policy by modeling accelerated access to non-addictive treatments, without mandating changes outside the VA.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Sen. Capito, Shelley Moore [R-WV]
Cosponsors (21)
Sen. Shaheen, Jeanne [D-NH], Sen. Cramer, Kevin [R-ND], Sen. King, Angus S., Jr. [I-ME], Sen. Hoeven, John [R-ND], Sen. Gillibrand, Kirsten E. [D-NY], Sen. Ricketts, Pete [R-NE], Sen. Klobuchar, Amy [D-MN], Sen. Justice, James C. [R-WV], Sen. Kaine, Tim [D-VA], Sen. Britt, Katie Boyd [R-AL], Sen. Van Hollen, Chris [D-MD], Sen. Hagerty, Bill [R-TN], Sen. Kelly, Mark [D-AZ], Sen. Scott, Tim [R-SC], Sen. Cortez Masto, Catherine [D-NV], Sen. Rosen, Jacky [D-NV], Sen. Banks, Jim [R-IN], Sen. Booker, Cory A. [D-NJ], Sen. Hyde-Smith, Cindy [R-MS], Sen. Boozman, John [R-AR], Sen. Bennet, Michael F. [D-CO]
Recent Actions
- 2025-11-19: Read twice and referred to the Committee on Veterans' Affairs.
- 2025-11-19: Introduced in Senate
Bill Versions
- Non-Opioids Prevent Addiction in the Nation for Veterans Act — issued 2025-11-19 — PDF (3 pages)